Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 J+Clin+Med 2022 ; 11 (3): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices #MMPMID35160311
Volod O; Bunch CM; Zackariya N; Moore EE; Moore HB; Kwaan HC; Neal MD; Al-Fadhl MD; Patel SS; Wiarda G; Al-Fadhl HD; McCoy ML; Thomas AV; Thomas SG; Gillespie L; Khan RZ; Zamlut M; Kamphues P; Fries D; Walsh MM
J Clin Med 2022[Feb]; 11 (3): ä PMID35160311show ga
Viscoelastic hemostatic assay (VHAs) are whole blood point-of-care tests that have become an essential method for assaying hemostatic competence in liver transplantation, cardiac surgery, and most recently, trauma surgery involving hemorrhagic shock. It has taken more than three-quarters of a century of research and clinical application for this technology to become mainstream in these three clinical areas. Within the last decade, the cup and pin legacy devices, such as thromboelastography (TEG((R)) 5000) and rotational thromboelastometry (ROTEM((R)) delta), have been supplanted not only by cartridge systems (TEG((R)) 6S and ROTEM((R)) sigma), but also by more portable point-of-care bedside testing iterations of these legacy devices (e.g., Sonoclot((R)), Quantra((R)), and ClotPro((R))). Here, the legacy and new generation VHAs are compared on the basis of their unique hemostatic parameters that define contributions of coagulation factors, fibrinogen/fibrin, platelets, and clot lysis as related to the lifespan of a clot. In conclusion, we offer a brief discussion on the meteoric adoption of VHAs across the medical and surgical specialties to address COVID-19-associated coagulopathy.